| Autor: |
Edimar Alcides Bocchi, Ivna Girard Cunha Vieira Lima, Bruno Biselli, Vera Maria Cury Salemi, Silvia Moreira Ayub Ferreira, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Ranna Santos Pessoa, Francisco Akira Malta Cardoso, Mariana Vieira de Oliveira Bello, Ludhmila Abrahão Hajjar, Brenno Rizerio Gomes |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
ESC Heart Failure, Vol 8, Iss 2, Pp 943-952 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2055-5822 |
| DOI: |
10.1002/ehf2.13199 |
| Popis: |
Abstract Aims Patients with advanced heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and concurrent coronavirus disease 2019 (COVID‐19) might have a higher risk of severe events. Methods and results We retrospectively studied 16 patients with advanced HFrEF who developed COVID‐19 between 1 March and 29 May 2020. Follow‐up lasted until 30 September. Ten patients previously hospitalized with decompensated HFrEF were infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during hospitalization. Six patients undergoing ambulatory care at initiation of COVID‐19 symptoms were hospitalized because of advanced HFrEF. All patients who experienced worsening of HFrEF due to COVID‐19 required higher doses or introduction of additional inotropic drugs or intra‐aortic balloon pump in the intensive care unit. The mean intravenous dobutamine dose before SARS‐CoV‐2 infection in previously hospitalized patients (n = 10) and the median (inter‐quartile range) peak intravenous dobutamine dose during SARS‐CoV‐2 infection in all patients (n = 16) were 2 (0–7) μg/kg/min and 20 (14–20) (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text